One day we hope to be able to say — well, here’s a disease, and then click a button and out pops the design for a drug to ...

It will receive follow-on capital from existing backer Alphabet. The London-based company’s goal is an ambitious one – to “solve all disease,” according to the Isomorphic Labs site.

The latest to do so is Google parent company Alphabet, which has established Isomorphic Labs, under DeepMind head Demis Hassabis, to take its shot at the promising new field.

Isomorphic Labs, Google’s artificial intelligence drug business, raised $600 million in its first external funding round, the company said on Monday. Thrive Capital, a venture capital firm, led ...

Alphabet has spun off a new company called Isomorphic Labs which seeks to use artificial intelligence to discover new pharmaceutical drugs. The commercial venture will reportedly build off of ...

Isomorphic Labs, the Alphabet Inc.-owned company that uses artificial intelligence to discover drugs, has raised $600 million, the first time it’s taken in external funding.

In July, the company published a paper describing AlphaFold2, open-sourced the code, and dropped a library of 350,000 protein structures with a promise to add 100 million more. This week, Alphabet ...

Alphabet's AI drug development subsidiary Isomorphic Labs is aiming to initiate clinical trials for its AI-developed oncology drugs. In an interview with Fortune, Isomorphic Labs president Colin ...

Alphabet’s Isomorphic Labs, spun out of DeepMind, is preparing to start human trials of AI-designed drugs after raising $600 ...

Isomorphic Labs, a subsidiary of Alphabet Inc., is close to human trials for its AI-designed medicines. Other companies are ...

Isomorphic Labs is the secretive AI life sciences startup spun out of Google DeepMind with the goal of solving all disease with AI-powered drug discovery.

Isomorphic Labs sets up US presence in Cambridge, with an eye on clinical trials By Katie Palmer STAT,Updated June 17, 2025, 10:57 a.m.